Dossier assessment

Trifarotene (acne vulgaris) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A20-73
Last updated

Report documents

  1. Extract of dossier assessment

    Trifarotene (acne vulgaris) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 304 kB, EN, not accessible
  2. Dossier assessment

    Trifarotene (acne vulgaris) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 265 kB, DE, not accessible

Dossier assessment

Indication:

Patients from 12 years of age and older with acne vulgaris of the face and/or the trunk, when many comedones, papules and pustules are present

Result of dossier assessment:

Added benefit not proven due to a lack of suitable study data

Press releases

Trifarotene in moderate acne: no study data for the assessment of the added benefit

Only studies with placebo comparisons despite many affected people and existing treatment alternatives

Project details

Project no.
A20-73
Commission
Commission awarded on 13.08.2020 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Skin and hair
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form